Jul 2024 $20 M Private placement after listing $10 to $50 million 2
BioNanomatrix Inc: Private sale, Jul 2024 × Investors in this round 2 investors had bought by the notice of Jul 10, 2024: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $20 M of $20 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $400,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Alka A. Chaubey · Executive Officer Gulsen Erik Kama · Executive Officer Jonathan A. Dixon · Executive Officer Mark A. Oldakowski · Executive Officer R. Erik Holmlin · Executive Officer, Director Albert A. Luderer · Director Aleksandar A. Rajkovic · Director Christopher A. Twomey · Director David L. Barker · Director Hannah A. Mamuszka · Director Kristiina A. Vuori · Director Vincent A. Wong · Director Yvonne L. Linney · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in all US states Signed by R. Erik Holmlin, President and CEO. Source: SEC Form D, newest notice filed Jul 10, 2024. Read the notice at the SEC .
options SEC May 2024 $20 M Private placement after listing $10 to $50 million 4
BioNanomatrix Inc: Private sale, May 2024 × Investors in this round 4 investors had bought by the notice of Jun 5, 2024: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $20 M of $20 M offered
Smallest investment taken $100,000
What was sold equity, debt Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,275,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice R. Erik Holmlin · Executive Officer Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Canaccord Genuity LLC (CRD 1020) · New York, New York Sold in CT, NY Signed by R. Erik Holmlin, President and CEO. Source: SEC Form D, newest notice filed Jun 5, 2024. Read the notice at the SEC .
equity, debt SEC Oct 2023 $35 M Private placement after listing $10 to $50 million 1
BioNanomatrix Inc: Private sale, Oct 2023 × Investors in this round 1 investor had bought by the notice of Oct 27, 2023: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $35 M of $35 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Alka Chaubey, Ph.D., FACMG · Executive Officer Gulsen Kama · Executive Officer Mark Oldakowski · Executive Officer R. Erik Holmlin, Ph.D. · Executive Officer, Director Albert A. Luderer, Ph.D. · Director Aleksandar A. Rajkovic, M.D., Ph.D. · Director Christopher A. Twomey · Director David L. Barker, Ph.D. · Director Hannah A. Mamuszka · Director Kristiina A. Vuori, M.D., Ph.D. · Director Vincent A. Wong, J.D., M.B.A. · Director Yvonne A. Linney, Ph.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by R. Erik Holmlin, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 27, 2023. Read the notice at the SEC .
debt, options SEC Oct 2021 $42 M Private placement after listing $10 to $50 million 27
BioNanomatrix Inc: Private sale, Oct 2021 × Investors in this round 27 investors had bought by the notice of Oct 25, 2021: 8 accredited, 19 not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $42 M of $42 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Alka Chaubey, Ph.D., FACMG · Executive Officer Christopher Stewart · Executive Officer Jason A. Priar · Executive Officer Mark Oldakowski · Executive Officer R. Erik Holmlin, Ph.D. · Executive Officer, Director Richard A. Shippy · Executive Officer Soheil A. Shams · Executive Officer Albert A. Luderer, Ph.D. · Director Christopher A. Twomey · Director David L. Barker, Ph.D. · Director Hannah A. Mamuszka · Director Kristiina A. Vuori, M.D., Ph.D. · Director Yvonne A. Linney, Ph.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by R. Erik Holmlin, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 25, 2021. Read the notice at the SEC .
equity SEC Mar 2019 $3 M Private placement after listing $2 to $10 million 3
BioNanomatrix Inc: Private sale, Mar 2019 × Investors in this round 3 investors had bought by the notice of Mar 28, 2019: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $12 M offered; $9 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue not stated
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Mark Borodkin · Executive Officer Mike Ward · Executive Officer R. Erik Holmlin, Ph.D. · Executive Officer, Director Warren Robinson · Executive Officer Albert L. Luderer, Ph.D. · Director Christopher L. Twomey · Director Darren L. Cai, Ph.D. · Director David L. Barker, Ph.D. · Director Junfeng L. Wang · Director Quan L. Zhou · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by /s/ R. Erik Holmlin, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 28, 2019. Read the notice at the SEC .
equity SEC Sep 2014 $68 M No. 5 $50 to $250 million 17
BioNanomatrix Inc: Raise no. 5, Sep 2014 × Investors in this round 17 investors had bought by the notice of Jan 27, 2015: 17 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $68 M of $68 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, other: Securities offered consist of Warrants exercisable for shares of Series C Preferred Stock, the Series C Preferred Stock issuable upon exercise of the warrants and the common stock underlying the Serie Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Erik R. Holmlin · Executive Officer, Director Han R. Cao · Executive Officer Joel R. Jung · Executive Officer Albert R. Luderer · Director Brian R. Halak · Director Campbell R. Murray · Director Darren R. Cai · Director David R. Barker · Director Tracy R. Warren · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The amount listed above includes the amount receivable upon the exercise of warrants to purchase shares of Series C Preferred Stock. Such warrants have not yet been exercised.”Signed by Joel Jung, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 27, 2015. Read the notice at the SEC .
equity, options SEC Jun 2014 $5 M No. 4 $2 to $10 million 5
BioNanomatrix Inc: Raise no. 4, Jun 2014 × Investors in this round 5 investors had bought by the notice of Jun 27, 2014: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $6 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Han A. Cao · Executive Officer Joel R. Jung · Executive Officer R. Erik Holmlin · Executive Officer Albert A. Luderer · Director Brian L. Halak · Director David L. Barker · Director Tracy A. Warren · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Total offering amount listed above includes an aggregate of $1,039,997 receivable upon the exercise of warrants to purchase shares of the Company's Series B-1 Preferred Stock. Such warrants have not yet been exercised.”Signed by Joel Jung, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 27, 2014. Read the notice at the SEC .
debt, options SEC Sep 2013 $10 M No. 3 $10 to $50 million 5
BioNanomatrix Inc: Raise no. 3, Sep 2013 × Investors in this round 5 investors had bought by the notice of Oct 2, 2013: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $10 M of $14 M offered; $4 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Han A. Cao · Executive Officer R. Erik Holmlin · Executive Officer, Director Albert A. Luderer · Director Brian L. Halak · Director David L. Barker · Director Tracy A. Warren · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Total Offering Amount listed above includes an aggregate of $3,110,509 receivable upon the exercise of warrants to purchase shares of the Company's Series B-1 preferred stock. Such warrants have not yet been exercised.”Signed by Erik Holmlin, Ph.D., President and CEO. Source: SEC Form D, newest notice filed Oct 2, 2013. Read the notice at the SEC .
debt, options SEC Jun 2012 $12 M No. 2 $10 to $50 million 6
BioNanomatrix Inc: Raise no. 2, Jun 2012 × Investors in this round 6 investors had bought by the notice of Jul 5, 2012: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $12 M of $14 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Securities offered consist of shares of convertible preferred stock, the convertible preferred stock issued upon exercise of the warrants and the common stock underlying the convertible preferred stoc
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Garth A. Monroe · Executive Officer Han A. Cao · Executive Officer R. Erik Holmlin · Executive Officer, Director Albert A. Luderer · Director Brian L. Halak · Director David L. Barker · Director Tracy A. Warren · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Amounts listed above include an aggregate of $2,787,501 receivable upon the exercise of warrants to purchase shares of convertible preferred stock. Such warrants have not yet been exercised.”Signed by Garth Monroe, Cfo. Source: SEC Form D, newest notice filed Jul 5, 2012. Read the notice at the SEC .
equity, options SEC Mar 2011 $23 M No. 1 $10 to $50 million 9
BioNanomatrix Inc: Raise no. 1, Mar 2011 × Investors in this round 9 investors had bought by the notice of Mar 24, 2011: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.
What the notice says
Amount sold $23 M of $23 M offered
Smallest investment taken no minimum stated
What was sold equity, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Lorraine G. LoPresti · Executive Officer Robert Erik Holmlin · Executive Officer, Director Brian L. Halak · Director David L. Barker · Director Tracy Erik Warren · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Lorraine G. LoPresti, Cfo. Source: SEC Form D, newest notice filed Mar 24, 2011. Read the notice at the SEC .
equity SEC